Non-steroidal anti-inflammatory drugs and atherothrombotic risk in older patients: Where do we stand?

Age and Ageing

Volumn 39, Issue 5, 2010, Pages 530-533

  Mangoni, Arduino A ^a   Reid, David M ^a   Knights, Kathleen M ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Ageing; Atherothrombotic risk; Cardiovascular system; Inflammation; Non steroidal anti inflammatory drugs

Indexed keywords

ANTIHYPERTENSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ARTHRITIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DRUG ANTAGONISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART INFARCTION; HEART PROTECTION; HUMAN; INSTITUTIONALIZATION; KIDNEY FAILURE; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; STROKE;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATHEROSCLEROSIS; HUMANS; MIDDLE AGED; RISK FACTORS; THROMBOSIS;

EID: 77955946145     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afq099     Document Type: Article

References (28)

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81: 646-56.
2. Hawkey CJ. NSAIDs and aspirin: notorious or FAMOUS? Lancet 2009; 374: 93-4.
3. Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998; 47: S93-101.
4. Using NSAIDs in cardiovascular disease. Drug Ther Bull 2010; 48: 26-9.
5. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003; 65: 153-9.
6. Wilson SL, Poulter NR. The effect of non-steroidal antiinflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006; 24: 1457-69.
7. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6.
8. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-11.
9. Tegeder I, Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 1-17.
10. Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 2009; 68: 402-12.
11. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115: 1634-42.
12. MHRA Public Assessment Report - Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Risks in the General Population. (27 May 2010, date last accessed) http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm. 2010.
13. Solomon SD, Wittes J, Finn PV et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117: 2104-13.
14. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8.
15. CHMP Assessment Report for the Medicinal Products Containing Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). (21 May 2010, date last accessed) http://www.emea.europa.eu/pdfs/human/opiniongen/nsaids.pdf. 2006.
16. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44.
17. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628-36.
18. Fosbol EL, Gislason GH, Jacobsen S et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190-7.
19. Mangoni AA, Woodman RJ, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 2010; 19: 490-8.
20. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol 2010; 69: 689-700.
21. Dukkipati R, Adler S, Mehrotra R. Cardiovascular implications of chronic kidney disease in older adults. Drugs Aging 2008; 25: 241-53.
22. Carter JL, O'Riordan SE, Eaglestone GL, Delaney MP, Lamb EJ. Chronic kidney disease prevalence in a UK residential care home population. Nephrol Dial Transplant 2008; 23: 1257-64.
23. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
24. Franceschi C, Capri M, Monti D et al. Inflammaging and antiinflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92-105.
25. Widlansky ME, Price DT, Gokce N et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-5.
26. Liao CH, Liao CH, Chang YL et al. Effect of a potent cyclooxygenase inhibitor, 5-ethyl-4-methoxy-2-phenylquinoline (KTC-5), on human platelets. J Pharm Pharmacol 2002; 54: 967-74.
27. Thomas MC. Diuretics, ACE inhibitors and NSAIDs-the triple whammy. Med J Aust 2000; 172: 184-5.
28. The SCOT Trial. (27 May 2010, date last accessed) http://www.scottrial.co.uk/. 2008.